Kinnate Biopharma Inc. KNTE
Day range unavailable
52-week range unavailable
- Market cap
- 124.99M
- Shares out
- 47.17M
- Forward P/E
- -2.55
- Beta
- 1.34
- Analysts
- Buy
- Price target
- 2.36 (-10.9%)
- Earnings date
- May 9, 2024
Key statistics
- Enterprise value
- -38.87M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.72
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -59.61M
- Total cash
- 167.58M
- Total debt
- 3.38M
- Return on equity
- -55.80%
- Short % of float
- 1.55%
- 50-day average
- 2.49
- 200-day average
- 2.24
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 2.36
- Target (high)
- 2.59
- Strong buy3
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate -0.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 9, 2024 | Mar 1, 2024 | -0.36 | — | — | — |
| Apr 3, 2024 | Dec 1, 2023 | -0.45 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.69 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | -0.76 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -0.73 | — | — | — |
| Mar 15, 2023 | Dec 1, 2022 | -0.70 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2023 | Jefferies | main | Buy | Buy |
| Sep 18, 2023 | Wedbush | down | Outperform | Neutral |
| Sep 18, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 18, 2023 | Piper Sandler | down | Overweight | Neutral |
| Aug 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 7, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kinnate.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on KNTE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FORESITE CAPITAL MANAGEMENT IV, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 7, 2023 | 0 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 4, 2023 | 0 |
| KRISHNAMOHAN NEHA | Chief Financial Officer | Stock Award(Grant) | Aug 31, 2022 | 69,015 |
| MELTZ MARK A. | Chief Operating Officer | Stock Award(Grant) | Aug 31, 2022 | 28,465 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 4, 2023 | 0 |
| TANANBAUM JAMES B | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 7, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Foresite Capital Management IV, LLC | 20.54% | 9,671,643 | 29.31M | Jun 29, 2023 |
| Orbimed Advisors LLC. | 17.01% | 8,009,729 | 24.27M | Jun 29, 2023 |
| Foresite Capital Management V, LLC | 7.49% | 3,525,957 | 10.68M | Jun 29, 2023 |
| Nextech Invest Ag | 4.95% | 2,329,480 | 7.06M | Jun 29, 2023 |
| Vida Ventures Advisors, LLC | 4.69% | 2,207,772 | 3.09M | Sep 29, 2023 |
| Lynx1 Capital Management Lp | 4.35% | 2,048,736 | 6.21M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.55% | 730,663 | 2.21M | Jun 29, 2023 |
| Fidelity Select Portfolios - Biotechnology | 0.75% | 351,780 | 784.47K | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 0.46% | 215,647 | 653.41K | Jun 29, 2023 |
| BlackRock Health Sciences Term Trust | 0.42% | 196,773 | 596.22K | Jun 29, 2023 |
| iShares NASDAQ Biotechnology ETF | 0.30% | 139,853 | 311.87K | Aug 30, 2023 |
| Fidelity Extended Market Index Fund | 0.17% | 78,551 | 337.77K | May 30, 2023 |